


1657
RECEIVED

JAN 14 2002

TECH CENTER 1600/2900

PATENT APPLICATION
Attorney Docket No.: BURF-P01-006

DYH:kfd
October 22, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Fallon, et al.
Application No.: 09/715,836 Group Art Unit: 1651
Filed: November 17, 2000 Examiner: N/A
For: BIGLYCAN AND RELATED THERAPEUTICS AND
METHODS OF USE

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as
First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents,
United States Patent and Trademark Office, Washington, D.C. 20231.

October 22, 2001
Date

Karen DiRocco
Karen DiRocco

TRANSMITTAL OF SEQUENCE LISTING IN RESPONSE TO NOTICE TO
COMPLY WITH 37 C.F.R. §§1.821-1.825

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is submitted in response to the Notice to Comply with
Requirements for Patent Applications Containing Nucleotide Sequence and/or
Amino Acid Sequence Disclosures attached thereto, mailed from the Patent Office
on October 2, 2001, copies of which are attached.

Transmitted herewith is a copy of the "Sequence Listing" in paper form for the above-
identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence

Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Respectfully submitted,

ROPES & GRAY



David P. Halstead

Registration No. 44,735

Telephone (617) 951-7000

Facsimile (617) 951-7050

Boston, Massachusetts 02110

Date: October 22, 2001